22. Moyamoya disease Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 17 / Drugs : 22 - (DrugBank : 17) / Drug target genes : 33 - Drug target pathways : 45
Drugs and their primary sponsors and trial info
Aspirin
Beijing Tiantan Hospital, Capital Medical University
2019 - ChiCTR1800020377 China;
Capital Medical University
2019 - NCT04012268 China;
Qilu Hospital of Shandong University
2021 - ChiCTR2100046178 china;
Desflurane
The First Affiliated Hospital of Zhengzhou University
2019 Phase 4 ChiCTR1900027197 China;
Dl-3-n-butylphthalide (NBP)
yuanli Zhao
2020 Phase 3 NCT04205578 China;
Edaravone
Department of Neurosurgery, Hokkaido University Graduate School of Medicine
2012 - JPRN-UMIN000008742 Japan;
Erythropoietin
Ajou University School of Medicine
2010 Phase 1/Phase 2 NCT03162588 Korea, Republic of;
Seoul National University Hospital
2019 - NCT03882060 Korea, Republic of;
Fluorescein
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Gadobutrol
Aoki Shigeki
2018 - JPRN-jRCTs031180017 Japan;
Gadovist
Aoki Shigeki
2018 - JPRN-jRCTs031180017 Japan;
Indocyanine green
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Magnetic Resonance Imaging
Stanford University
2009 - NCT01419275 United States;
Norepinephrine
The South District of Anhui Provincial Hospital
2021 Phase 4 ChiCTR2000041260 China;
2020 Phase 4 ChiCTR2000029878 China;
Normal Saline Infusion Solution
yuanli Zhao
2020 Phase 3 NCT04205578 China;
Normal saline
Seoul National University Hospital
2019 - NCT03882060 Korea, Republic of;
Phenylephrine
The South District of Anhui Provincial Hospital
2021 Phase 4 ChiCTR2000041260 China;
2020 Phase 4 ChiCTR2000029878 China;
Propofol
The First Affiliated Hospital of Zhengzhou University
2019 Phase 4 ChiCTR1900027197 China;
RIC
Capital Medical University
2019 - NCT04012268 China;
Sevoflurane
Seoul National University Hospital
2015 - NCT02510586 -
Water
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Xenon contrast agent
Stanford University
2009 - NCT01419275 United States;
Beijing Tiantan Hospital, Capital Medical University
2019 - ChiCTR1800020377 China;
Capital Medical University
2019 - NCT04012268 China;
Qilu Hospital of Shandong University
2021 - ChiCTR2100046178 china;
Desflurane
The First Affiliated Hospital of Zhengzhou University
2019 Phase 4 ChiCTR1900027197 China;
Dl-3-n-butylphthalide (NBP)
yuanli Zhao
2020 Phase 3 NCT04205578 China;
Edaravone
Department of Neurosurgery, Hokkaido University Graduate School of Medicine
2012 - JPRN-UMIN000008742 Japan;
Erythropoietin
Ajou University School of Medicine
2010 Phase 1/Phase 2 NCT03162588 Korea, Republic of;
Seoul National University Hospital
2019 - NCT03882060 Korea, Republic of;
Fluorescein
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Gadobutrol
Aoki Shigeki
2018 - JPRN-jRCTs031180017 Japan;
Gadovist
Aoki Shigeki
2018 - JPRN-jRCTs031180017 Japan;
Indocyanine green
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Magnetic Resonance Imaging
Stanford University
2009 - NCT01419275 United States;
Norepinephrine
The South District of Anhui Provincial Hospital
2021 Phase 4 ChiCTR2000041260 China;
2020 Phase 4 ChiCTR2000029878 China;
Normal Saline Infusion Solution
yuanli Zhao
2020 Phase 3 NCT04205578 China;
Normal saline
Seoul National University Hospital
2019 - NCT03882060 Korea, Republic of;
Phenylephrine
The South District of Anhui Provincial Hospital
2021 Phase 4 ChiCTR2000041260 China;
2020 Phase 4 ChiCTR2000029878 China;
Propofol
The First Affiliated Hospital of Zhengzhou University
2019 Phase 4 ChiCTR1900027197 China;
RIC
Capital Medical University
2019 - NCT04012268 China;
Sevoflurane
Seoul National University Hospital
2015 - NCT02510586 -
Water
Akiyama Hideo
2021 - JPRN-jRCTs031200402 Japan;
Xenon contrast agent
Stanford University
2009 - NCT01419275 United States;